| Data | Hora | Fonte | Título | Código | Companhia |
| 11/10/2013 | 17:46 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(g) (15-12g) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 02/10/2013 | 07:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 17:43 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 17:19 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 17:14 | Edgar (US Regulatory) | Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 17:05 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 09:58 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 07:34 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 07:21 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 01/10/2013 | 07:00 | PR Newswire (US) | Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 18/09/2013 | 18:30 | PR Newswire (US) | Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 17/09/2013 | 09:30 | Marketwired | Onyx Pharmaceuticals Announces Data Presentations at 2013 European Cancer Congress | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 10/09/2013 | 10:47 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 09/09/2013 | 09:08 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 05/09/2013 | 20:44 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 03/09/2013 | 07:34 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 03/09/2013 | 07:08 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 30/08/2013 | 03:30 | PR Newswire (US) | Bayer's Stivarga® (regorafenib) Tablets Approved in Europe | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 29/08/2013 | 16:44 | PR Newswire (US) | ONYX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiducia... | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 28/08/2013 | 20:00 | Business Wire | Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches an Investigation of Onyx Pharmaceuticals, Inc. Over the Proposed Sa... | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 28/08/2013 | 05:30 | Zacks | Bull of the Day: Biogen Idec (BIIB) - Bull of the Day | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 19:09 | Business Wire | Rigrodsky & Long, P.A. Announces Investigation Of Onyx Pharmaceuticals, Inc. Buyout | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 17:33 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 12:15 | Dow Jones News | Correction to Bayer, Onyx FDA Priority Review Story | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 11:47 | PR Newswire (US) | Ryan & Maniskas, LLP Announces Investigation of Onyx Pharmaceuticals, Inc. | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 08:00 | Dow Jones News | Bayer, Onxy Get FDA Priority Review for Sorafenib For Type of Cancer | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 04:15 | Dow Jones News | Bayer: FDA Priority Review for Nexavar Treatment of Thyroid Cancer | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 27/08/2013 | 03:30 | PR Newswire (US) | Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug Applic... | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 26/08/2013 | 22:36 | PR Newswire (US) | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Ony... | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |
| 26/08/2013 | 21:38 | PR Newswire (US) | Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareh... | NASDAQ:ONXX | Onyx Pharmaceuticals, Inc. (MM) |